Edited by
George Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.
George Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.
Elizabeth Jaffee, Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.
Elizabeth Jaffee, Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.
Description
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This
book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can
be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent
studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular
targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides
basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how
applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced
disease.
Audience:
Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients
